Medical bioremediation of age-related diseases

Jacques M. Mathieu, John Schloendorn, Bruce Rittmann, Pedro J J Alvarez

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Catabolic insufficiency in humans leads to the gradual accumulation of a number of pathogenic compounds associated with age-related diseases, including atherosclerosis, Alzheimer's disease, and macular degeneration. Removal of these compounds is a widely researched therapeutic option, but the use of antibodies and endogenous human enzymes has failed to produce effective treatments, and may pose risks to cellular homeostasis. Another alternative is "medical bioremediation," the use of microbial enzymes to augment missing catabolic functions. The microbial genetic diversity in most natural environments provides a resource that can be mined for enzymes capable of degrading just about any energy-rich organic compound. This review discusses targets for biodegradation, the identification of candidate microbial enzymes, and enzyme-delivery methods.

Original languageEnglish (US)
Article number21
JournalMicrobial cell factories
Volume8
DOIs
StatePublished - Apr 9 2009

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Fingerprint Dive into the research topics of 'Medical bioremediation of age-related diseases'. Together they form a unique fingerprint.

  • Cite this